In this transnational twenty-first century, Asian countries have tried to harness biotechnology as an alternative way to increase economic productivity, promote health and wealth, and to ensure national security. Several notable entrepreneurial successes in biotechnology have emerged in Asia. ReproCELL, a biotech firm based on Nobel-prize winning research on human iPS cells at Kyoto University, went public in 2013 with a record-setting IPO in Japan. In Shenzen, China's Silicon Valley, Sibiono Genetech developed a blockbuster cancer drug in 2004. Biocon, India's leading biopharmaceutical company, operates India's largest biologics facility, and its market valuation reached $2.4 billion in 2016. Celligenics, established by a foreign scientist entrepreneur, is one of the innovative biotech companies established in Singapore's biotech cluster.
Kathryn C. Ibata-Arens's Beyond Technonationalism develops a synthetic-analytic framework that can illuminate some of these recent entrepreneurial successes in Asia's biomedical industry. Ultimately, it presents Asian countries’ evolutions from the developmental state model...
